Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG37466

ARL8B Knockout Hela Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Uterus (cervix)

  • Disease:

    Adenocarcinoma

The ARL8B Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the ARL8B gene. ARL8B encodes a lysosomal Arf-like GTPase that, upon activation by the BORC complex, recruits effector SKIP (PLEKHM2) and kinesin-1 (KIF5B) to drive anterograde lysosome transport, thereby regulating lysosomal positioning, exocytosis, and mTORC1 signaling. This knockout model in the HeLa cervical adenocarcinoma line is ideal for studying lysosomal trafficking, autophagy, mTOR signaling, and cancer cell migration. Representative assays include immunofluorescence microscopy, Lysotracker staining, migration/invasion tests, and autophagy flux measurements.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HeLa

    Sex of Donor

    Female

    Age

    31 years

    Gene Name

    ARL8B

    Gene Identifier

    NCBI Gene ID 55207

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    MEM (with NEAA)

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The ARL8B Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, providing a heterogeneous loss-of-function model. This non-clonal population captures diverse editing outcomes without single-cell cloning, enabling robust studies of ARL8B-dependent processes.

HeLa cells are an immortalized human cervical adenocarcinoma line (HPV18 positive) widely used for their robust growth, ease of manipulation, and well-characterized signaling pathways. As a cancer-derived epithelial model, HeLa endogenously expresses endolysosomal and mTOR pathway components, making them suitable for dissecting ARL8B-mediated lysosomal functions.

ARL8B is a small Arf-like GTPase that localizes to lysosomes and acts as a central regulator of lysosomal motility and positioning. Activated by the BORC complex (BLOS1, BLOS2, KXD1, SNAPIN), ARL8B recruits SKIP (PLEKHM2) to the lysosomal surface, linking lysosomes to kinesin-1 (KIF5B) motors for anterograde transport toward the periphery. Thus, ARL8B controls lysosomal exocytosis, mTORC1 signaling, and autophagic flux through spatial regulation. It also interacts with HOPS complex components (VPS39, VPS41) for lysosomal fusion. Upstream, lysosomal stress and mTORC1 feed back to modulate BORC-ARL8B, positioning ARL8B as a key node in endolysosomal trafficking.

In HeLa cells, ARL8B disruption likely impairs anterograde lysosome transport, causing perinuclear clustering and altered lysosomal functions. This model is relevant for cancer cell migration/invasion, as lysosomal positioning influences focal adhesion turnover and matrix degradation. HeLa cells are also a key system for mTORC1 signaling, which depends on lysosomal surface residency; thus, ARL8B knockout provides insights into nutrient sensing and autophagy regulation.

Researchers can employ this model in assays such as western blotting for protein loss, immunofluorescence microscopy for lysosome positioning, Lysotracker staining, co-immunoprecipitation of ARL8B-SKIP, kinesin motor assays, and cell migration/invasion tests. Downstream signaling readouts include mTORC1 activity (phospho-S6K) and autophagy flux (LC3-II turnover). Transcriptome analysis via RNA-seq can reveal ARL8B-dependent networks. For further information, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)